Corbus Pharmaceuticals Granted Fast Track Status for Investigational Drug Resunab(TM) to Treat Systemic Sclerosis
This week, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced that Resunabâ„¢, has been granted Fast Track status for the clinical investigation of  by the U.S. Food and Drug Administration (FDA) for the treatment of systemic sclerosis…